A phase 3 trial of Roche’s possible Tamiflu replacement in people at high risk of complications from the flu is meeting its goals.
Ogilvy CommonHealth Worldwide recruited Samantha Dolin, an Evoke and Digitas ex, to head up creative in the region.
Pfizer has again suspended production at a long-troubled sterile injectables plant in India that the FDA has twice before cited.
A new lawsuit in Tennessee says Purdue targeted "pill mills" to boost sales for OxyContin.
Certain valsartan drugs made by Teva, Major Pharmaceuticals and Solco Healthcare—the U.S. subsidiary of the API supplier in question—are being recalled.
Amgen is facing major competitive threats to some of its biggest sellers, meaning an acquisition could be in order.
Thanks to Mylan’s price cut on generic Copaxone, Teva’s going to have to take the price on its branded product down. And it may be wise to start now.
Pfizer and Astellas’ prostate cancer med Xtandi nabbed broader FDA approval, setting it up for a head-to-head fight with J&J’s Erleada.
We’re looking for women in biotech, pharma and medtech who stand out as leaders, innovators and mentors in organizations big and small.
BioMarin and Believe Limited are helping 25 high schoolers create the first-ever musical about bleeding disorders.
.jpg/syringe-1973129_1280 (1).jpg?3_a2XYaRx8S33MRAd7DoWiTT4RBWfpMD&itok=sm_6Tfk9 "syringe")
